• SELECT SITE CURRENCY
Select a currency for use throughout the site
The Top 20 Developers of Molecular Diagnostic Tests for Lung Cancer
Research Facts Ltd, August 2010, Pages: 50
According to the World Health Organization’s International Agency for Research on Cancer, lung cancer has been the most common cancer in the world for several decades and by 2008, there were an estimated 1.61 million new cases, representing 12.7% of all new cancers. It was also the most common cause of death from cancer, with 1.38 million deaths.
Lung cancer is the most common cancer in men worldwide (1.1 million cases), with high rates in Central-Eastern and Southern Europe, Northern America and Eastern Asia. In females, incidence rates are generally lower, but worldwide, lung cancer is now the fourth most frequent cancer of women (513,000 cases, 8.5% of all cancers) and the second most common cause of death from cancer (427,000 deaths). The highest incidence rate is observed in Northern America (where lung cancer it is now the second most frequent cancer in women) and the lowest in Middle Africa (15th most frequent cancer).
This report profiles the top 20 developers of molecular diagnostic tests for lung cancer. These companies have either developed or are in the process of developing tests for e.g.:
- Screening and Early Detection
- Differentiation of the Histological Sub-Classes of Non-Small Cell Lung Cancer
- Identifying Those Lung Cancer Patients at a Higher and Lower Risk of Mortality after Surgery
- Selection of Candidate Patients For Adjuvant Chemotherapy
Profile information for each company in The Top 20 Developers of Molecular Diagnostic Tests For Lung Cancer typically includes:
- Company Contact Information - Address, Telephone and Fax Numbers, Email and Website Address
- Key Company Decision Makers - From CEO and Main Board, to Key Senior Managers
- Specialised fields such as Company Description, Ownership, Products, Technology, Year Established, Number of Employees, Turnover and Foreign Trade.
Report Target Market:
1) Molecular Diagnostics Companies
Usage: competitive/financial analysis and strategic partner/alliance identification.
This report is perfect for suppliers of e.g. contract manufacturing services who wish to identify top potential customers.
The Top 20 Developers of Molecular Diagnostic Tests for Lung Cancer is ideal for distributors with experience in distributing high-complexity molecular diagnostic tests in the oncology field, to identify the leading developers with the latest products.
4) Pharmaceutical & Biotechnology Companies
This report is very useful to those pharmaceutical and biotechnology companies that are interested in pharmacogenomics and developing personalised medicines.
5) MDx Laboratories & Cancer Research Centres
As it identifies all the leading developers of molecular diagnostic tests for lung cancer, this report is of great interest to laboratories performing molecular diagnostic tests and organisations carrying out cancer research.
Note: Most people will be aware of some of the major developers of molecular diagnostic tests such as Innogenetics, Qiagen and Roche, but this report looks at all 20 of the top developers of molecular diagnostic tests for lung cancer – companies like Allegro Diagnostics – founded in 2006, the Massachusetts, United States based company is a leader in the field of gene expression molecular diagnostic testing for lung cancer and other epithelial diseases.
Report data field structure is as follows:
- Company Name
- Mailing Address
- Street Address
- Parent Company Name
- Year Established
- Number of Employees
- Key Executives
- Company Description
- Turnover €m
- Foreign Trade
- Location Status
Research Facts’ reports help you make informed decisions about the markets and organisations that affect your business.
- Learn more about your target markets and target companies
- Top level research on all the major players in a market
- See which organisations dominate your major markets
- Get detailed information on particular organisations
Research Facts is a world leader in healthcare and life sciences publishing. It was established in Dublin, Ireland in 2004. Its partners have over forty years combined experience in the business information industry. Research Facts’ customers include most of the world’s major diagnostics, pharmaceutical, biotechnology and medical device companies e.g. Roche, Abbott, Johnson & Johnson, Wyeth, Medtronic, Siemens Medical, Philips Healthcare, Thermo Fisher Scientific, Covance, GE Healthcare, Ipsen, Edwards Lifesciences, B Braun, Teva, Biomet, Smith & Nephew, Boehringer Ingelheim, DePuy, Bayer, Qiagen, Intuitive Surgical etc..
Research Facts has customers right across the globe e.g. Australia, Belgium, Brazil, Canada, Cyprus, Denmark, France, Germany, Finland, Hungary, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mauritius, Netherlands, Pakistan, Portugal, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States and Yugoslavia.
Keywords: Molecular Diagnostics, Lung Cancer.
- 20/20 Gene Systems
- Abbott Molecular
- Allegro Diagnostics, Inc.
- Biodesix, Inc.
- Cangen Biotechnologies
- CeMines, Inc.
- Clarient, Inc.
- Epigenomics AG
- Gene Express, Inc.
- Genomic Health, Inc.
- Med BioGene Inc.
- Medical Prognosis Institute A/S
- OncoMethylome Sciences S.A.
- Orion Genomics
- Qiagen Manchester Ltd (DxS)
- Response Genetics, Inc.
- Rosetta Genomics
- SomaLogic, Inc.
- Source MDx
- TrovaGene, Inc.